Ultra-hypofractionated for Whole Breast Irradiation (WBI) Compared to Partial Breast Irradiation (PBI) - Trial NCT05914831
Access comprehensive clinical trial information for NCT05914831 through Pure Global AI's free database. This Phase 2 trial is sponsored by Oncology Institute of Vojvodina and is currently Recruiting. The study focuses on Breast Cancer Female. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Oncology Institute of Vojvodina
Timeline & Enrollment
Phase 2
Jun 01, 2023
May 31, 2033
Primary Outcome
Acute toxicity,Late toxicity
Summary
Female patients undergoing surgical treatment for early breast cancer and meeting the
 inclusion criteria for adjuvant breast radiotherapy were randomized into two groups. One
 group will receive adjuvant whole-breast radiotherapy in ultra-hypofractionated regimen of 26
 Gy in 5 fractions. In contrast, the other group will receive partial breast irradiation with
 a dose of 26Gy in 5 fractions.
 
 The study's objective is to compare the effects of both breast radiotherapy protocols in
 terms of locoregional disease control and survival and to compare the adverse effects of
 radiotherapy between the two protocols. To determine if there is a correlation between
 different parameters and the efficacy and degree of toxicity for both protocols.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05914831
Non-Device Trial